News from alligator bioscience A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Apr 01, 2022, 02:19 ET Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort Commences

Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the completion of the patient enrollment for the 600 mg dose cohort from Alligator's...

Mar 23, 2022, 04:06 ET Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kg

Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the ongoing OPTIMIZE-1 clinical Phase Ib/II trial in first-line...

Feb 11, 2022, 02:22 ET Alligator Bioscience AB: Year End report January-December 2021

OPTIMIZE-1 Phase II - On Track and Moving Forward "During the fourth quarter 2021, Alligator reached several key milestones in our pre-clinical,...

Feb 01, 2022, 02:20 ET Alligator Bioscience Appoints Sumeet Ambarkhane MD as Chief Medical Officer

Alligator Bioscience (Nasdaq Stockholm: ATORX) Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces the appointment of Sumeet Ambarkhane,...

Jan 19, 2022, 02:41 ET Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory Beatty

Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the initiation a sponsored research collaboration to study biomarker data from...

Jan 18, 2022, 02:16 ET Alligator Bioscience Announces OPTIMIZE-1 Trial Update: Cohort Fully Dosed with No Adverse Effects Reported

Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the on-going OPTIMIZE-1 clinical Phase Ib/II trial with the company's...

Dec 16, 2021, 02:39 ET Alligator Bioscience Announces Trial Update and Early Readout for ATOR-1017 Confirming Biomarker, Safety & Tolerability Data

Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the on-going clinical Phase I trial with the 4-1BB (CD137) drug candidate ...

Dec 15, 2021, 08:36 ET Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal Nature Communication

Alligator Bioscience AB ("Alligator") and Aptevo Therapeutics ("Aptevo") (NASDAQ: APVO) today announced publication of an article in the December 15, ...

Nov 08, 2021, 11:53 ET Alligator Bioscience Announces Commencement of Investigator Initiated Phase I Clinical Trial at Erasmus University Rotterdam

Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the initiation of a proof-of-concept Phase Ib clinical trial to assess the safety and...

Oct 21, 2021, 02:41 ET Alligator Bioscience AB: Interim report January-September 2021

First Patient Dosed in Optimize-1 Phase II "We continued to make great strides in the third quarter of 2021. The first patient was dosed in...

Oct 07, 2021, 02:23 ET Notice of extraordinary general meeting in Alligator Bioscience AB

The shareholders of Alligator Bioscience AB, Reg. No. 556597-8201 ("Alligator"), are invited to the extraordinary general meeting to be held on...

Sep 02, 2021, 06:14 ET Alligator is exploring financing alternatives to support phase II studies for Mitazalimab, phase II preparations for ATOR-1017 as well as the development of other pipeline

Alligator Bioscience AB ("Alligator" or the "Company") today announces that the Company, in order to enable further progress, will begin evaluating...

Sep 02, 2021, 04:33 ET Positive Results from the Scandion Oncology and Alligator Bioscience Collaboration Further Supports Efficacy of Mitazalimab in Combination Therapy

Alligator Bioscience AB (Nasdaq Stockholm: ATORX) and Scandion Oncology A/S (Nasdaq Stockholm: SCOL), today announced the conclusion of their...

Aug 18, 2021, 02:49 ET Alligator Bioscience announces Immuno-oncology Research Collaboration and License Agreement with Orion Corporation

Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that the company has entered into a research collaboration and license agreement with...

Aug 16, 2021, 09:13 ET Alligator Bioscience Announces New Senior Director of Communications & Investor Relations

Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that Julie Silber has joined the company as the new Senior Director of Communications...

Jul 13, 2021, 02:41 ET Alligator Bioscience AB: Interim report January-June 2021

Positive Phase I data for ATOR-1017 "As new CEO of Alligator Bioscience, after just around a month, let me say that my high expectations on the...

Jul 13, 2021, 02:31 ET Alligator Bioscience AB: Interim report January-June 2021

Positive Phase I data for ATOR-1017 "As new CEO of Alligator Bioscience, after just around a month, let me say that my high expectations on the...

Jun 30, 2021, 03:08 ET Alligator Bioscience AB and Scandion Oncology A/S present promising preclinical data

Alligator Bioscience (Nasdaq Stockholm: ATORX) and Scandion Oncology (Nasdaq Stockholm: SCOL) today announces promising preclinical data from their...

Jun 07, 2021, 02:21 ET Article on CD40 agonistic antibodies published in Expert Opinion on Biological Therapy

Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the scientific journal Expert Opinion on Biological Therapy has published an...

Jun 04, 2021, 02:18 ET Alligator Bioscience presents positive Phase I data at ASCO for its 4-1BB agonist drug candidate ATOR-1017

Alligator Bioscience (Nasdaq Stockholm: ATORX) today presents novel supportive data from the ongoing Phase I clinical trial with the 4-1BB (CD137)...

Jun 01, 2021, 09:08 ET Bulletin from the annual general meeting in Alligator Bioscience AB on June 1, 2021

Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the annual general meeting was held in the company this day. In light of the...

May 05, 2021, 02:21 ET Alligator's mitazalimab shown to enhance cancer vaccine

Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that preclinical data on its agonist anti-CD40 antibody mitazalimab has been published ...

May 04, 2021, 02:18 ET Alligator Bioscience and BioArctic enter into research agreement in the neurodegenerative field

Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it has entered into a joint research agreement with BioArctic AB, a Swedish...

Apr 27, 2021, 02:21 ET Alligator Bioscience AB: Interim report January-March 2021

High activity during the first quarter "So far, 2021 has been characterized by high activity, with a research collaboration that validates our...

Apr 22, 2021, 13:44 ET The Nomination Committee's proposal regarding the board of directors ahead of the annual general meeting 2021 in Alligator Bioscience AB

Ahead of the annual general meeting in Alligator Bioscience AB on June 1, 2021, the Nomination Committee announces its proposals regarding Chairman...